rabbit polyclonal anti bub1b  (Proteintech)

Journal: Discover Oncology

Article Title: Integrated transcriptomic and immunoinformatics analysis identifies tpx2 , bub1b , and ube2c as diagnostic biomarkers and therapeutic targets in endometrial carcinoma

doi: 10.1007/s12672-025-03800-9

Figure Lengend Snippet: Comparative mRNA expression analysis of hub genes in endometrial carcinoma (EC) tissues. A Relative expression levels of ten key genes ( aurka , bub1b , ccnb1 , cdc20 , cdk1 , chek1 , rad51 , tpx2 , tyms , and ube2c ) in EC versus normal tissues based on the GSE63678 ( n = 12; 7 EC and 5 normal) and GSE17025 ( n = 103) datasets. B Unpaired analysis of mRNA expression using the GEPIA platform, showing significant upregulation of all ten genes in EC tumor samples ( n = 147) compared to normal controls ( n = 91). C Paired analysis of tumor versus adjacent normal tissues ( n = 23 pairs) using the Xiantao platform, confirming consistent overexpression of these genes. These findings support the transcriptional upregulation of the selected hub genes in EC and reinforce their potential as diagnostic and therapeutic targets

Article Snippet: The expression of AURKA (Proteintech, Wuhan, China, A00246-4), BUB1B (Proteintech, Wuhan, China, 83920-6RR), TPX2 (Proteintech, Wuhan, China, 11741-1-AP), and UBE2C (Proteintech, Wuhan, China, 12134-2-AP) was assessed using immunohistochemistry (IHC).

Techniques: Expressing, Over Expression, Diagnostic Assay, Biomarker Discovery

Journal: Discover Oncology

Article Title: Integrated transcriptomic and immunoinformatics analysis identifies tpx2 , bub1b , and ube2c as diagnostic biomarkers and therapeutic targets in endometrial carcinoma

doi: 10.1007/s12672-025-03800-9

Figure Lengend Snippet: Immunohistochemical detection of AURKA, BUB1B, TPX2, and UBE2C expression in EC and normal endometrial tissues (400× magnification). Panels A–D represent AURKA, BUB1B, TPX2, and UBE2C expression in normal endometrial tissues, respectively; Panels E–H represent the corresponding expression in endometrial carcinoma tissues. Scale bars are included in all panels for reference. Negative controls (isotype/secondary antibody–only) were performed during staining optimization to confirm antibody specificity but are not shown here; representative examples are available upon request

Article Snippet: The expression of AURKA (Proteintech, Wuhan, China, A00246-4), BUB1B (Proteintech, Wuhan, China, 83920-6RR), TPX2 (Proteintech, Wuhan, China, 11741-1-AP), and UBE2C (Proteintech, Wuhan, China, 12134-2-AP) was assessed using immunohistochemistry (IHC).

Techniques: Immunohistochemical staining, Expressing, Staining

Journal: Discover Oncology

Article Title: Integrated transcriptomic and immunoinformatics analysis identifies tpx2 , bub1b , and ube2c as diagnostic biomarkers and therapeutic targets in endometrial carcinoma

doi: 10.1007/s12672-025-03800-9

Figure Lengend Snippet: Prognostic and diagnostic significance of hub genes in endometrial carcinoma (EC). ( A ) Kaplan–Meier survival curves showing overall survival differences in EC patients with high vs. low expression of ten hub genes. Genes such as aurka , bub1b , tpx2 , and ube2c showed significant associations with poor survival. ( B ) Receiver operating characteristic (ROC) curves evaluating the diagnostic accuracy of each hub gene for EC. All genes demonstrated strong diagnostic power, with AUC values above 0.88, and ube2c showing the highest AUC (0.971)

Article Snippet: The expression of AURKA (Proteintech, Wuhan, China, A00246-4), BUB1B (Proteintech, Wuhan, China, 83920-6RR), TPX2 (Proteintech, Wuhan, China, 11741-1-AP), and UBE2C (Proteintech, Wuhan, China, 12134-2-AP) was assessed using immunohistochemistry (IHC).

Techniques: Diagnostic Assay, Expressing

Journal: Discover Oncology

Article Title: Integrated transcriptomic and immunoinformatics analysis identifies tpx2 , bub1b , and ube2c as diagnostic biomarkers and therapeutic targets in endometrial carcinoma

doi: 10.1007/s12672-025-03800-9

Figure Lengend Snippet: Expression patterns of bub1b , tpx2 , and ube2c across clinical stages and histological grades in endometrial carcinoma (EC). A–C Box plots showing transcript levels of bub1b , tpx2 , and ube2c across clinical stages I–IV based on TCGA-UCEC data from the UALCAN platform. All three genes demonstrate consistently elevated expression across progressive tumor stages. D–F mRNA expression of the same genes analyzed by histological grade (G1–G3) using TCGA data. Gene expression levels increase with higher tumor grade, supporting their role in disease aggressiveness. All comparisons show statistical significance ( P < 0.01), highlighting the potential of bub1b , tpx2 , and ube2c as markers of both EC onset and progression. Box plots display the median, interquartile range (IQR), and whiskers representing 1.5× IQR; individual dots indicate outliers. Thus, the error bars represent data spread based on IQR rather than standard deviation (SD) or standard error of the mean (SEM)

Article Snippet: The expression of AURKA (Proteintech, Wuhan, China, A00246-4), BUB1B (Proteintech, Wuhan, China, 83920-6RR), TPX2 (Proteintech, Wuhan, China, 11741-1-AP), and UBE2C (Proteintech, Wuhan, China, 12134-2-AP) was assessed using immunohistochemistry (IHC).

Techniques: Expressing, Gene Expression, Standard Deviation

Journal: Discover Oncology

Article Title: Integrated transcriptomic and immunoinformatics analysis identifies tpx2 , bub1b , and ube2c as diagnostic biomarkers and therapeutic targets in endometrial carcinoma

doi: 10.1007/s12672-025-03800-9

Figure Lengend Snippet: Correlation between hub gene expression and immune cell infiltration in endometrial carcinoma (EC). Scatter plots generated using the TIMER 2.0 platform show the relationship between the expression levels of ( A ) bub1b , ( B ) tpx2 , and ( C ) ube2c with tumor purity and various immune cell populations, including B cells, CD8⁺ T cells, CD4⁺ T cells, macrophages, neutrophils, and dendritic cells. Partial correlation coefficients (partial.cor) and p-values indicate significant negative associations between gene expression and immune infiltration, particularly for neutrophils and dendritic cells, suggesting an immunosuppressive tumor microenvironment linked to overexpression of these genes

Article Snippet: The expression of AURKA (Proteintech, Wuhan, China, A00246-4), BUB1B (Proteintech, Wuhan, China, 83920-6RR), TPX2 (Proteintech, Wuhan, China, 11741-1-AP), and UBE2C (Proteintech, Wuhan, China, 12134-2-AP) was assessed using immunohistochemistry (IHC).

Techniques: Gene Expression, Generated, Expressing, Over Expression

Journal: International journal of molecular sciences

Article Title: A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma.

doi: 10.3390/ijms26052061

Figure Lengend Snippet: Figure 1. Pan-cancer analysis of BUB1B expression. (A) Differential expression of BUB1B between tumor and normal tissues in pan-cancer analysis. (B,C) Expression of BUB1B in various cancer cell lines and tissues. (D,E) Cellular localization of BUB1B from U-251MG and U2OS. ** p < 0.01, *** p < 0.001.

Article Snippet: The information for antibodies was as follows: BUB1B (Boster, Wuhan, China), vimentin (CST, Danvers, MA, USA), E-cadherin (CST, MA, USA), N-cadherin (CST, MA, USA), and GAPDH (CST, MA, USA).

Techniques: Expressing, Quantitative Proteomics

Journal: International journal of molecular sciences

Article Title: A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma.

doi: 10.3390/ijms26052061

Figure Lengend Snippet: Figure 2. BUB1B expression correlates with overall survival time (OS). GEPIA2 analyses of the association between BUB1B expression and OS in (A) ACC, (B) KIRC, (C) KIRP, (D) LGG, (E) LIHC, (F) LUAD, (G) MESO, (H) PAAD, (I) SARC, and (J) THYM.

Article Snippet: The information for antibodies was as follows: BUB1B (Boster, Wuhan, China), vimentin (CST, Danvers, MA, USA), E-cadherin (CST, MA, USA), N-cadherin (CST, MA, USA), and GAPDH (CST, MA, USA).

Techniques: Expressing

Journal: International journal of molecular sciences

Article Title: A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma.

doi: 10.3390/ijms26052061

Figure Lengend Snippet: Figure 3. Correlation between BUB1B expression and mutations in various cancer types. (A) Land- scape of BUB1B mutation in 32 cancer types, (B) the subtypes and distributions of BUB1B somatic mutations, (C,D) Spearman correlation analysis for TMB, MSI, and BUB1B gene expression. In the figure, the horizontal axis represents the correlation coefficient between the genes and TMB, and the vertical axis represents the different tumors. The size of the dots in the figure represents the correlation coefficient, and the different colors represent the significance of the p value. The bluer the color in the diagram, the smaller the p value.

Article Snippet: The information for antibodies was as follows: BUB1B (Boster, Wuhan, China), vimentin (CST, Danvers, MA, USA), E-cadherin (CST, MA, USA), N-cadherin (CST, MA, USA), and GAPDH (CST, MA, USA).

Techniques: Expressing, Mutagenesis, Gene Expression

Journal: International journal of molecular sciences

Article Title: A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma.

doi: 10.3390/ijms26052061

Figure Lengend Snippet: Figure 4. The association between BUB1B expression and immune cell infiltration. (A,B) BUB1B expression is positively associated with MDSC infiltration in pan-cancer. (C,D) BUB1B expression is positively negative with NKT cell infiltration in pan-cancer. (E–H) BUB1B expression is negative associated with the infiltration level of B cells, macrophage cells, CD4+ T cells, and CD8+ T cells.

Article Snippet: The information for antibodies was as follows: BUB1B (Boster, Wuhan, China), vimentin (CST, Danvers, MA, USA), E-cadherin (CST, MA, USA), N-cadherin (CST, MA, USA), and GAPDH (CST, MA, USA).

Techniques: Expressing

Journal: International journal of molecular sciences

Article Title: A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma.

doi: 10.3390/ijms26052061

Figure Lengend Snippet: Figure 5. The enrichment analysis of BUB1B co-expression genes in LUAD. (A) The BUB1B co- expression genes in LUAD. (B,C) The top 50 genes positively and negatively correlated to BUB1B. (D,E) GO and KEGG analysis of BUB1B co-expression genes in the LUAD cohort.

Article Snippet: The information for antibodies was as follows: BUB1B (Boster, Wuhan, China), vimentin (CST, Danvers, MA, USA), E-cadherin (CST, MA, USA), N-cadherin (CST, MA, USA), and GAPDH (CST, MA, USA).

Techniques: Expressing

Journal: International journal of molecular sciences

Article Title: A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma.

doi: 10.3390/ijms26052061

Figure Lengend Snippet: Figure 6. Function of BUB1B in LUAD determined using the CancerSEA database. (A) Analysis from the CancerSEA database at single-cell resolution indicated that BUB1B was primarily involved in cell cycle, proliferation, DNA damage, DNA repair, invasion, inflammation, quiescence. (B,C) Functional relevance in LUAD, BUB1B expression was significantly positively correlated with cell cycle, pro- liferation, DNA damage, DNA repair, invasion, and was negatively correlated with inflammation, quiescence. The experiments were repeated three times. (* p < 0.05, ** p < 0.01, *** p < 0.001).

Article Snippet: The information for antibodies was as follows: BUB1B (Boster, Wuhan, China), vimentin (CST, Danvers, MA, USA), E-cadherin (CST, MA, USA), N-cadherin (CST, MA, USA), and GAPDH (CST, MA, USA).

Techniques: Functional Assay, Expressing

Journal: International journal of molecular sciences

Article Title: A Comprehensive Analysis Revealing BUB1B as a Potential Prognostic and Immunological Biomarker in Lung Adenocarcinoma.

doi: 10.3390/ijms26052061

Figure Lengend Snippet: Figure 7. Cellular functions of BUB1B. (A,B) Western blot and RT-qPCR detection after siRNA- mediated knockdown of BUB1B in A549 cells. (C) CCK-8 assay results showing the decrease in the viability of A549 cells upon the knockdown of BUB1B. (D,E) Wound healing test. (F,G) Transwell assay results showing the decrease in the migration in A549 cells upon the knockdown of BUB1B. (H,I) Western blot results showing the decrease in the EMT progression in A549 cells upon the knockdown of BUB1B. All experiments were repeated three times with three replicates for each repeat. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Article Snippet: The information for antibodies was as follows: BUB1B (Boster, Wuhan, China), vimentin (CST, Danvers, MA, USA), E-cadherin (CST, MA, USA), N-cadherin (CST, MA, USA), and GAPDH (CST, MA, USA).

Techniques: Western Blot, Quantitative RT-PCR, Knockdown, CCK-8 Assay, Transwell Assay, Migration